Skip to main content
    H

    Humana Inc (HUM)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NYSE

    $461.15
    +11.15 (+2.48%)

    Market Cap: $54.05B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Humana Inc (HUM) Earnings: Report Dates and Results

    Updated Nov 6, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Humana (HUM) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Humana reported EPS of -$0.70, above the -$1.03 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    95%(38/40)
    Avg Surprise
    +6.32%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$7.60
    Range-$7.68 - -$6.94
    27 analysts
    Revenue Consensus
    $41.98B
    Range$40.05B - $46.75B
    21 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$13.15
    Range$11.21 - $15.60
    15 analysts
    EPS Revisions
    4
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$12.24+7.5%
    60d ago$12.21+7.7%
    30d ago$12.33+6.7%
    7d ago$12.33+6.7%
    Current$13.15
    Revenue Consensus
    $42.99B
    Range$41.13B - $44.94B
    10 analysts

    Next Report

    HUM has an expected report date of Feb 9, 2027.

    HUM Earnings Call

    The latest HUM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, HUM beat 38 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $41.16B, up 26.1% from $32.65B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.70-$1.03-$1.16 - -$0.60+32.04%Beat-121.6%230 up, 4 downNov 6, 2026$41.16B
    Jun 30, 2026$7.61$6.22$1.61 - $7.94+22.35%Beat+21.4%245 up, 1 downJul 29, 2026$40.87B
    Mar 31, 2026$10.31$10.20$8.08 - $12.98+1.08%Beat-11.0%233 up, 0 downApr 29, 2026$39.65B
    Dec 31, 2025-$3.96-$3.99-$4.33 - -$3.45+0.75%BeatN/A240 up, 22 downFeb 11, 2026$32.52B
    Sep 30, 2025$3.24$2.91$0.66 - $3.35+11.34%Beat-22.1%250 up, 1 downNov 5, 2025$32.65B
    Jun 30, 2025$6.27$5.87$4.50 - $8.28+6.81%Beat-9.9%233 up, 2 downJul 30, 2025$32.39B
    Mar 31, 2025$11.58$10.07$8.53 - $10.92+14.99%Beat+60.2%232 up, 2 downApr 30, 2025$32.11B
    Dec 31, 2024-$2.16-$2.12-$2.52 - -$1.10-1.89%MissN/A232 up, 0 downFeb 11, 2025$29.21B
    Sep 30, 2024$4.16$3.39$2.68 - $3.90+22.71%Beat-46.5%221 up, 0 downOct 30, 2024$29.40B
    Jun 30, 2024$6.96$5.86$4.96 - $6.74+18.77%Beat-22.1%210 up, 0 downJul 31, 2024$29.54B
    Mar 31, 2024$7.23$6.00$5.76 - $8.11+20.50%Beat-22.9%191 up, 0 downApr 24, 2024$29.61B
    Dec 31, 2023-$0.11$0.92-$0.12 - $2.15-111.96%Miss-106.8%110 up, 6 downJan 25, 2024$26.46B
    Sep 30, 2023$7.78$7.17$7.05 - $7.53+8.51%Beat+13.1%191 up, 0 downNov 1, 2023$26.42B
    Jun 30, 2023$8.94$8.83$8.14 - $9.20+1.25%Beat+3.1%211 up, 0 downAug 2, 2023$26.75B
    Mar 31, 2023$9.38$9.20$8.98 - $9.46+1.96%Beat+16.7%191 up, 2 downApr 26, 2023$26.74B
    Dec 31, 2022$1.62$1.46$1.35 - $1.66+10.96%Beat+30.6%200 up, 0 downFeb 1, 2023$22.44B
    Sep 30, 2022$6.88$6.28$6.15 - $6.53+9.55%Beat+42.4%183 up, 0 downNov 2, 2022$22.80B
    Jun 30, 2022$8.67$7.67$7.36 - $8.05+13.04%Beat+25.8%210 up, 1 downJul 27, 2022$23.66B
    Mar 31, 2022$8.04$6.80$6.44 - $7.20+18.24%Beat+4.8%202 up, 0 downApr 27, 2022$23.97B
    Dec 31, 2021$1.24$1.16$1.06 - $1.77+6.90%BeatN/A210 up, 0 downFeb 2, 2022$21.05B
    Sep 30, 2021$4.83$4.67$4.28 - $5.12+3.43%Beat+56.8%190 up, 1 downNov 3, 2021$20.70B
    Jun 30, 2021$6.89$6.84$6.02 - $7.86+0.73%Beat-45.1%21N/AJul 28, 2021$20.64B
    Mar 31, 2021$7.67$7.10$6.65 - $8.63+8.03%Beat+42.0%19N/AApr 28, 2021$20.67B
    Dec 31, 2020-$2.30-$2.32-$2.44 - -$2.24+0.86%Beat-200.9%19N/AFeb 3, 2021$19.06B
    Sep 30, 2020$3.08$2.80$2.50 - $3.21+10.00%Beat-38.8%23N/ANov 3, 2020$20.07B
    Jun 30, 2020$12.56$10.12$9.55 - $11.74+24.11%Beat+107.6%22N/AAug 5, 2020$19.08B
    Mar 31, 2020$5.40$4.69$4.46 - $5.73+15.14%Beat+20.5%20N/AApr 29, 2020$18.93B
    Dec 31, 2019$2.28$2.19$2.14 - $2.24+4.11%Beat-14.0%23N/AFeb 5, 2020$16.30B
    Sep 30, 2019$5.03$4.57$4.42 - $4.82+10.07%Beat+9.8%23N/ANov 6, 2019$16.24B
    Jun 30, 2019$6.05$5.27$4.49 - $5.47+14.80%Beat+52.8%21N/AJul 31, 2019$16.25B
    Mar 31, 2019$4.48$4.30$4.14 - $4.48+4.19%Beat+33.3%21N/AMay 1, 2019$16.11B
    Dec 31, 2018$2.65$2.53$2.49 - $2.57+4.74%Beat+28.6%21N/AFeb 6, 2019$14.17B
    Sep 30, 2018$4.58$4.24$3.81 - $4.42+8.02%Beat+35.1%20N/ANov 7, 2018$14.21B
    Jun 30, 2018$3.96$3.78$3.70 - $3.87+4.76%Beat+13.5%19N/AAug 1, 2018$14.26B
    Mar 31, 2018$3.36$3.20$3.08 - $3.25+5.00%Beat+22.2%17N/AMay 2, 2018$14.28B
    Dec 31, 2017$2.06$2.00$1.95 - $2.12+3.00%Beat-1.4%20N/AFeb 7, 2018$13.19B
    Sep 30, 2017$3.39$3.27$3.10 - $3.42+3.67%Beat+6.6%14N/ANov 8, 2017$13.28B
    Jun 30, 2017$3.49$3.06$2.85 - $3.30+14.05%Beat+51.7%18N/AAug 2, 2017$13.53B
    Mar 31, 2017$2.75$2.63N/A+4.56%Beat+47.8%N/AN/AMay 3, 2017$13.76B
    Dec 31, 2016$2.09$2.06N/A+1.46%Beat+44.1%N/AN/AFeb 8, 2017$12.88B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $17.13, up 5.8% from the year before. It was $9.43 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$17.13+5.8%
    Dec 31, 2024$16.19-37.7%
    Dec 31, 2023$25.99+3.1%
    Dec 31, 2022$25.21+22.2%
    Dec 31, 2021$20.63+10.1%
    Dec 31, 2020$18.74+5.0%
    Dec 31, 2019$17.84+22.6%
    Dec 31, 2018$14.55+24.5%
    Dec 31, 2017$11.69+24.0%
    Dec 31, 2016$9.43N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,600 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,55915
    2026Q2Jun 30, 20267,57317
    2026Q1Mar 31, 20268,27319
    2025Q4Dec 31, 20259,15921
    2025Q3Sep 30, 20257,47721
    2025Q2Jun 30, 20256,78119
    2025Q1Mar 31, 20256,60220
    2024Q4Dec 31, 20247,88218

    2026Q3 Earnings Call

    Opening remarks

    Lisa Stoner Vice President of Investor Relations Thank you, and good morning. We will begin this morning with brief remarks from Jim Rechtin, Humana's President and Chief Executive Officer, and Chief Financial Officer Celeste Mellet. Following these remarks, we will host a question-and-answer session with industry analysts. Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our third quarter 2026 earnings press release as they relate to forward-looking statements, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. Today's press release and posted remarks, our historical financial news releases, and our filings with the SEC are also available on our Investor Relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Any reference to earnings per share or EPS made during this conference call refers to diluted earnings per common share. Finally, this call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. With that, I'll turn it over to Jim.

    James Rechtin President and Chief Executive Officer Thank you, Lisa. Good morning, everyone, and thank you for joining us. We have just one headline today, and that is that we are in a good place. Execution is strong and improving, signs point to our strategy working, and we are increasingly seeing the tangible results of our team's good work. The results are positive for our members, our patients, and their health, and the results are contributing to our margin and earnings growth recovery, which is moving from on plan toward being ahead of the plan. As usual, I will frame my comments today around the four drivers of our business: one, product and experience, which drive customer retention and growth; two, clinical excellence, which delivers clinical outcomes and medical margin; three, highly efficient operations; and four, capital allocation and growth in both CenterWell and Medicaid. Let's start with product and experience. Our 2026 membership, both new and returning, is performing in line with or better than expected. Our 2027 product positioning also appears to be in line with expectations.

    Frequently Asked Questions About HUM

    When is Humana's next earnings date?

    Humana's next earnings report is expected for Feb 9, 2027.

    Did HUM beat earnings estimates last quarter?

    Yes. Humana reported EPS of -$0.70 for the quarter ended Sep 30, 2026, above the -$1.03 estimate, a 32.04% surprise.

    What EPS do analysts expect from HUM next quarter?

    The consensus EPS estimate for Humana for the quarter ending Dec 31, 2026 is -$7.60 from 27 analysts, with estimates from -$7.68 to -$6.94.

    How often does HUM beat earnings estimates?

    Humana beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +10.93%.